

Anti-Vedolizumab Antibody (8J813)

Product Details

| | |
|---------------|---------------------------|
| Ig Type: | IgG, κ |
| Conjugation: | Unconjugated |
| Clone: | 8J813 |
| Purification: | Protein A affinity column |

Applications

| | |
|--------------|--|
| Application: | ELISA, Sandwich ELISA, Competitive ELISA |
| Recommended | ELISA: 0.01-1 $\mu\text{g/ml}$; Sandwich ELISA: 0.5-2 $\mu\text{g/ml}$; Competitive ELISA: 5-10 $\mu\text{g/ml}$ |

Properties

| | |
|----------------------|--|
| Stability & Storage: | The lyophilized product store at -20°C or -80°C for 12 months. The reconstituted antibody can be stored at 2°C - 8°C for 2-3 weeks or at -20°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Shipping: | Shipping with blue ice. |

Antigen Details

| | |
|------------|--|
| Immunogen: | Vedolizumab |
| Synonyms: | MLN-002;MLN-0002;MLN002;Entyvio;LDP-02;LDP02 |

Research Background

Vedolizumab is a humanized monoclonal antibody used primarily for the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. The drug functions by specifically targeting the integrin $\alpha 4\beta 7$, a molecule that facilitates the migration of white blood cells into the gastrointestinal (GI) tract. By blocking this interaction, Vedolizumab reduces inflammation within the GI tract, providing relief from the symptoms associated with IBD. The drug is administered intravenously and is known for its gut-selective mechanism of action, which limits systemic immune suppression and focuses treatment effects on the GI tract. It was approved by the FDA in 2014 and is marketed under the brand name Entyvio.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481